Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment.
Taylor
S
S
Division of Immunity and Infection, University of Birmingham Medical School, UK.
Ferguson
N M
NM
Cane
P A
PA
Anderson
R M
RM
Pillay
D
D
D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D003521:Cyclopropanes; D016049:Didanosine / Q000627:therapeutic use*; D004784:Environmental Monitoring; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology* / Q000821:virology; D015497:HIV-1 / Q000254:growth & development / Q000302:isolation & purification*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D010078:Oxazines / Q000627:therapeutic use*; D012661:Semen / Q000821:virology*; D013997:Time Factors; D019562:Viral Load
D000480:Alkynes; D000998:Antiviral Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D019259:Lamivudine; C098320:efavirenz; D016049:Didanosine; D006918:Hydroxyurea